RT Journal Article
SR Electronic
T1 Randomized controlled trial transfusing convalescent plasma as post-exposure prophylaxis against SARS-CoV-2 infection
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.13.21267611
DO 10.1101/2021.12.13.21267611
A1 Shoham, Shmuel
A1 Bloch, Evan M
A1 Casadevall, Arturo
A1 Hanley, Daniel
A1 Lau, Bryan
A1 Gebo, Kelly
A1 Cachay, Edward
A1 Kassaye, Seble G.
A1 Paxton, James H.
A1 Gerber, Jonathan
A1 Levine, Adam C
A1 Currier, Judith
A1 Patel, Bela
A1 Allen, Elizabeth S.
A1 Anjan, Shweta
A1 Appel, Lawrence
A1 Baksh, Sheriza
A1 Blair, Paul W.
A1 Bowen, Anthony
A1 Broderick, Patrick
A1 Caputo, Christopher A
A1 Cluzet, Valerie
A1 Cordisco, Marie Elena
A1 Cruser, Daniel
A1 Ehrhardt, Stephan
A1 Forthal, Donald
A1 Fukuta, Yuriko
A1 Gawad, Amy L.
A1 Gniadek, Thomas
A1 Hammel, Jean
A1 Huaman, Moises A.
A1 Jabs, Douglas A.
A1 Jedlicka, Anne
A1 Karlen, Nicky
A1 Klein, Sabra
A1 Laeyendecker, Oliver
A1 Lane, Karen
A1 McBee, Nichol
A1 Meisenberg, Barry
A1 Merlo, Christian
A1 Mosnaim, Giselle
A1 Park, Han-Sol
A1 Pekosz, Andrew
A1 Petrini, Joann
A1 Rausch, William
A1 Shade, David M.
A1 Shapiro, Janna R.
A1 Singleton, J. Robinson
A1 Sutcliffe, Catherine
A1 Thomas, David L.
A1 Yarava, Anusha
A1 Zand, Martin
A1 Zenilman, Jonathan M.
A1 Tobian, Aaron A.R.
A1 Sullivan, David
YR 2021
UL http://medrxiv.org/content/early/2021/12/14/2021.12.13.21267611.abstract
AB BACKGROUND The efficacy of SARS-CoV-2 convalescent plasma (CCP) for preventing infection in exposed, uninfected individuals is unknown. We hypothesized that CCP might prevent infection when administered before symptoms or laboratory evidence of infection.METHODS This double-blinded, phase 2 randomized, controlled trial (RCT) compared the efficacy and safety of prophylactic high titer (≥1:320) CCP with standard plasma. Asymptomatic participants aged ≥18 years with close contact exposure to a person with confirmed COVID-19 in the previous 120 hours and negative SARS-CoV-2 test within 24 hours before transfusion were eligible. The primary outcome was development of SARS-CoV-2 infection.RESULTS 180 participants were enrolled; 87 were assigned to CCP and 93 to control plasma, and 170 transfused at 19 sites across the United States from June 2020 to March 2021. Two were excluded for SARS-CoV-2 RT-PCR positivity at screening. Of the remaining 168 participants, 12/81 (14.8%) CCP and 13/87 (14.9%) control recipients developed SARS-CoV-2 infection; 6 (7.4%) CCP and 7 (8%) control recipients developed COVID-19 (infection with symptoms). There were no COVID-19-related hospitalizations in CCP and 2 in control recipients. There were 28 adverse events in CCP and 58 in control recipients. Efficacy by restricted mean infection free time (RMIFT) by 28 days for all SARS-CoV-2 infections (25.3 vs. 25.2 days; p=0.49) and COVID-19 (26.3 vs. 25.9 days; p=0.35) were similar for both groups.CONCLUSION In this trial, which enrolled persons with recent exposure to a person with confirmed COVID-19, high titer CCP as post-exposure prophylaxis appeared safe, but did not prevent SARS-CoV-2 infection.Trial Registration Clinicaltrial.gov number NCT04323800.Competing Interest StatementDr. Cachay: Research funding: Gilead Science, Merck Sharp & Dohme, Dr. Shoham: Research funding: Ansun, Merck, Gilead, Emergent Biosultions; DSMB: Adamis, Karyopharm, Intermountain Health; consulting: Celltrion, Adagio, Immunone, Jannssen, Clinical TrialNCT04323800.Funding StatementThis study was funded principally by the U.S. Department of Defense Joint Program Executive Office for Chemical, Biological, Radiological and Nuclear Defense (JPEO-CBRND), in collaboration with the Defense Health Agency (DHA) (contract number: W911QY2090012), with additional support from Bloomberg Philanthropies, State of Maryland, the National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases 3R01AI152078-01S1, NIH National Center for Advancing Translational Sciences U24TR001609-S3 and UL1TR003098, Mental Wellness Foundation, Moriah Fund, Octapharma, HealthNetwork Foundation and the Shear Family Foundation The study sponsors did not contribute to the study design; the collection, analysis, and interpretation of data; manuscript preparation, and the decision to submit the paper for publication.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Approval was obtained from the Institutional Review Boards at Johns Hopkins University School of Medicine functioning as single IRB for all participating sites. An independent data and safety monitoring board provided oversight and reviewed efficacy and safety as the study was conducted. All participants provided written informed consent.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors